Notably, high GHRH-R expression in rectal tumors has been associated with poor tumor regression following neoadjuvant chemoradiotherapy, highlighting the potential of targeting GHRH-R with antagonists in patients who respond poorly to treatment [32]. Here, GHRHR is linked to rectal neoplasm.